Somatostatin analogues for pancreatic surgery

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  Gurusamy, Kurinchi Selvan ^a   Koti, Rahul ^a   Fusai, Giuseppe ^a   Davidson, Brian R ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; DRUG DERIVATIVE; GASTROINTESTINAL AGENT; OCTREOTIDE;

ADVERSE EVENT; CHEMOPROPHYLAXIS; EVIDENCE BASED MEDICINE; HUMAN; LENGTH OF STAY; META ANALYSIS; PANCREAS FISTULA; PANCREAS SURGERY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REOPERATION; REVIEW; SURGICAL MORTALITY; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; MORTALITY; PANCREAS; PANCREAS DISEASE; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PUBLISHING; SECRETION (PROCESS); SEPSIS; STATISTICS;

GASTROINTESTINAL AGENTS; HUMANS; LENGTH OF STAY; OCTREOTIDE; PANCREAS; PANCREATECTOMY; PANCREATIC DISEASES; PANCREATIC FISTULA; PANCREATICODUODENECTOMY; POSTOPERATIVE COMPLICATIONS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REOPERATION; SEPSIS; SOMATOSTATIN;

EID: 84880789969     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008370.pub3     Document Type: Review

References (91)

1. Beguiristain A, Espi A, Balen E, Pardo F, Hernandez Lizoain JL, Alvarez Cienfuegos J. Somatostatin prophylaxis following cephalic duodenopancreatectomy. Revista Espanola de Enfermedades Digestivas 1995;87(3):221-4.
2. Briceño Delgado FJ, López Cillero P, Rufián Peña S, Solórzano Peck G, Miño Fugarolas G, Pera Madrazo C. Prospective and randomized study on the usefulness of octreotide in the prevention of complications after cephalic duodeno-pancreatectomy. Revista Espanola de Enfermedades Digestivas 1998;90(10):687-94.
3. Buccoliero F, Pansini GC, Mascoli F, Mari C, Donini A, Navarra G. Somatostatin in duodenocephalopancreatectomy for neoplastic pathology. Minerva Chirurgica 1992;47(8):713-6.
4. Buchler M, Friess H. Inhibition of pancreatic secretion to prevent postoperative complications following pancreatic resection. Acta Gastroenterologica Belgica 1993; Vol. 56, issue 3-4:271-8.
5. Buchler M, Friess H. Prevention of postoperative complications following pancreatic surgery. Digestion 1993;54(Suppl 1):41-6.
6. Buchler M, Friess H, Klempa I, Hermanek P, Sulkowski U, Becker H, et al.Role of octreotide in the prevention of postoperative complications following pancreatic resection. American Journal of Surgery 1992;163(1):125-31.
7. Friess H, Klempa I, Hermanek P, Sulkowski U, Uhl W, Beger HG, et al.Prophylaxis of complications after pancreatic surgery: results of a multicenter trial in Germany. Digestion 1994; Vol. 55, issue Suppl 1:35-40.
8. Fernandez-Cruz L, Chavarria EJ, Taura P, Vallejos R, Lopez-Boado MA, Ferrer J. Prospective, randomized trial of the effect of octreotide on pancreatic juice output after pancreatoduodenectomy in relation to histological diagnosis, duct size and leakage. HPB 2012;14:91-2.
9. Buchler MM, Gaus W. Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis. authors' reply. British Journal of Surgery 1996; Vol. 83, issue 3:422-3.
10. Friess H, Beger HG, Sulkowski U, Becker H, Hofbauer B, Dennler HJ, et al.Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis. British Journal of Surgery 1995;82(9):1270-3.
11. Friess H, Beger HG, Sulkowski U, Becker H, Hofbauer B, Dennler HJ, et al.Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis (vol 82, pg 1270, 1995). British Journal of Surgery 1996; Vol. 83, issue 1:126.
12. Friess H, Hofbauer B, Buchler MW. The role of somatostatin and octreotide in pancreatic surgery and in acute and chronic pancreatitis. Digestive Surgery 1994;11(3-6):445-50.
13. Gouillat C, Chipponi J, Baulieux J, Partensky C, Saric J, Gayet B. Randomized controlled multicentre trial of somatostatin infusion after pancreaticoduodenectomy. British Journal of Surgery 2001;88(11):1456-62.
14. Gouillat C, Faucheron JL, Balique JG, Gayet B, Saric J, Partensky C, et al.Natural history of the pancreatic stump after duodenopancreatectomy of the pancreatic head. Annales de Chirurgie 2002;127(6):467-76.
15. Hesse UJ, De Decker C, Houtmeyers P, Demetter P, Ceelen W, Pattyn P, et al.Prospectively randomized trial using perioperative low-dose octreotide to prevent organ-related and general complications after pancreatic surgery and pancreatico-jejunostomy. World Journal of Surgery 2005;29(10):1325-8.
16. Hesse UJ, De Decker C, Houtmeyers P, Demetter P, Ceelen W, Pattyn P, et al.Prospectively randomized trial using perioperative low dose octreotide to prevent organ related and general complications following pancreatic surgery and pancreatico-jejunostomy. Acta Chirurgica Belgica 2005; Vol. 105, issue 4:383-7.
17. Katsourakis A, Oikonomou L, Chatzitheoklitos E, Noussios G, Pitiakoudis M, Polychronidis A, et al.The role of somatostatin in 67 consecutive pancreatectomies: a randomized clinical trial. Clinical and Experimental Gastroenterology 2010;3(1):179-83.
18. Katsourakis A, Zezos P, Noussios G, Kouklakis G, Chatzitheoklitos E, Simopoulos K, et al.Does prophylactic administration of somatostatin decrease the rates of complications after pancreatic resection?: a clinical and electron microscopy study. Pancreas 2013;42(1):37-41.
19. Klempa I, Baca I, Menzel J, Schuszdiarra V. Effect of somatostatin on basal and stimulated exocrine pancreatic secretion after partial duodenopancreatectomy. A clinical experimental study. Der Chirurg 1991; Vol. 62, issue 4:293-9.
20. Kollmar O, Moussavian MR, Richter S, de Roi P, Maurer CA, Schilling MK. Prophylactic octreotide and delayed gastric emptying after pancreaticoduodenectomy: results of a prospective randomized double-blinded placebo-controlled trial. European Journal of Surgical Oncology 2008;34(8):868-75.
21. Kurumboor P, Kamalesh NP, Pramil K, Vipin IS, Shylesh A, Varma D, et al.A prospective randomized controlled trial on use of octreotide in patients with soft pancreas undergoing pancreaticoduodenectomy: interim analysis. HPB 2012;14:225.
22. Lange JR, Steinberg SM, Doherty GM, Langstein HN, White DE, Shawker TH, et al.A randomized, prospective trial of postoperative somatostatin analogue in patients with neuroendocrine tumors of the pancreas. Surgery 1992;112(6):1033-8.
23. Matheus A, Montagnini A, Abe E, Haddad L, Penteado S, Abdo E, et al.Octreotide in patients with high risk to develop pancreatic fistula after pancreaticoduodenectomy: a prospective randomized trial. HPB 2010;12(Suppl S1):218-9.
24. Matheus AS, Montagnini AL, Jukemura J, Abe ES, Penteado S, Haddad LB, et al.Octreotide in patients with high risk to develop pancreatic fistula after pancreaticoduodenectomy - a prospective randomized trial. European Journal of Surgical Oncology 2010;36(9):814.
25. Matheus AS, Montagnini AL, Jukemura J, Perini MV, Haddad LB, Abe ES, et al.Does octreotide have any beneficial effect in patients with high risk to develop pancreatic fistula after pancreaticoduodenectomy: a prospective randomized trial. Gastroenterology 2009;136(5 Suppl 1):A-881.
26. Montorsi M, Zago M, Mosca F, Capussotti L, Zotti E, Ribotta G, et al.Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial. Surgery 1995;117(1):26-31.
27. Bassi C, Falconi M, Lombardi D, Briani G, Vesentini S, Camboni MG, et al.Prophylaxis of complications after pancreatic surgery: results of a multicenter trial in Italy. Italian Study Group. Digestion 1994;55(Suppl 1):41-7.
28. Pederzoli P, Bassi C, Falconi M, Camboni MG. Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. British Journal of Surgery 1994;81(2):265-9.
29. Ramos-De la Medina A, Sarr MG. Somatostatin analogues in the prevention of pancreas-related complications after pancreatic resection. Journal of Hepatobiliary Pancreatic Surgery 2006;13(3):190-3.
30. Sarr MG. The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. Journal of the American College of Surgeons 2003;196(4):556-65.
31. Shan YS, Sy ED, Lin PW. Role of somatostatin in the prevention of pancreatic stump-related morbidity following elective pancreaticoduodenectomy in high-risk patients and elimination of surgeon-related factors: prospective, randomized, controlled trial. World Journal of Surgery 2003;27(6):709-14.
32. Shan YS, Sy ED, Tsai ML, Tang LY, Li PS, Lin PW. Effects of somatostatin prophylaxis after pylorus-preserving pancreaticoduodenectomy: increased delayed gastric emptying and reduced plasma motilin. World Journal of Surgery 2005;29(10):1319-24.
33. Oberlin P, Suc B, Pezet D, Fagniez PL, Hay JM. Prevention of intra-abdominal complications after pancreatic resection by octreotide. A prospective, multicenter, randomized trial. Gastroenterology 2000;118(4):A463.
34. Suc B, Msika S, Piccinini M, Fourtanier G, Hay JM, Flamant Y, et al.Octreotide in the prevention of intra-abdominal complications following elective pancreatic resection: a prospective, multicenter randomized controlled trial. Archives of Surgery 2004;139(3):288-94.
35. Tulassay Z, Flautner L, Fehervari I, Sandor Z, Nemeth J. Somatostatin in the prevention of postoperative increase of pancreatic enzyme after pancreatic surgery. Orvosi Hetilap 1992;133(13):777-80.
36. Tulassay Z, Flautner L, Sandor Z, Fehervari I. Perioperative use of somatostatin in pancreatic surgery. Acta Biomedica Ateneo Parmense 1993;64(5-6):205-11.
37. Yeo CJ, Cameron JL, Lillemoe KD, Sauter PK, Coleman J, Sohn TA, et al.Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Annals of Surgery 2000;232(3):419-29.
38. Barnett SP, Hodul PJ, Creech S, Pickleman J, Arahna GV. Octreotide does not prevent postoperative pancreatic fistula or mortality following pancreaticoduodenectomy. The American Surgeon 2004;70(3):222-7.
39. Bassi C, Falconi M, Pederzoli P. Role of somatostatin and somatostatin analogs in the treatment of gastrointestinal-diseases - prevention of complications after pancreatic surgery. Gut 1994;35:S20-2.
40. Brennan MF, Yeo CJ, Warshaw AL, O'Leary P, Warren KW, Way LW, et al.Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial - discussion. Annals of Surgery 2000;232(3):426-9.
41. Büchler MW, Bassi C, Fingerhut A, Klempa I. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy?. Annals of Surgery 2001;234(2):262-3.
42. Droeser RA, Jeanmonod P, Schuld J, Moussavian MR, Schilling MK, Kollmar O. Octreotide prophylaxis is not beneficial for biochemical activity and clinical severity of postoperative pancreatic fistula after pancreatic surgery. Digestive Surgery 2013;29(6):484-91.
43. Elhadad A, Rounanier G, Chippoini J. Octreotide in the prevention of surgical complications after pancreatectomy. A prospective randomised multicenter study. Hepatogastroenterology 1998;45(Suppl 2):152.
44. Falconi M, Contro C, Ballabio M, Bassi C, Salvia R, Pederzoli P. Evaluation of lanreotide effects on human exocrine pancreatic secretion after a single dose: preliminary study. Digestive and Liver Disease 2002;34(2):127-32.
45. Frick T. Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis. British Journal of Surgery 1996;83(3):422-3.
46. Friess H, Buchler M, Meschenmoser L. Effect of octreotide (SMS 201-995) on exocrine pancreatic function in man. Pancreas 1989;4:616.
47. Friess H, Buchler M. Efficacy of somatostatin and its analogues in pancreatic surgery and pancreatic disorders. Digestion 1996;57 Suppl 1:97-102.
48. Habib E, Elhadad A, Fourtanier G, Chipponi J, Faniez P L, Hay JM, et al.Octreotide in prevention of surgical complication after pancreatectomy. Annales de Chirurgie 1998;52(7):671-2.
49. Klempa I, Schwedes U, Usadel KH. Prevention of postoperative pancreatic complications following duodenopancreatectomy using somatostatin. Der Chirurg 1979;50(7):427-31.
50. Lowy AM, Lee JE, Davidson BS, Pisters PWT, Evans DB. The role of octreotide in the prevention of pancreatic fistula after pancreaticoduodenectomy for periampullary malignancy: a prospective randomized trial. Gastroenterology 1996;110(4):A1401.
51. Lowy AM, Lee JE, Pisters PW, Davidson BS, Fenoglio CJ, Stanford P, et al.Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Annals of Surgery 1997;226(5):632-41.
52. Shatverian GA, Ratnikova NP, Mikhailov Iu E, Bedzhanian AL, Sidorov AN, Fisenko EP, et al.Role octreotide in prevention of complications after pancreatoduodenal resections [Rol' oktreotida v profilaktuke oslozhnenii posle pankreatoduodenal'nykh rezektsii]. Khirurgiia 2004;2:56-60.
53. Van Berge Henegouvven MI, Van Gulik TM, Akkermans LMA, Jansen JBMJ, Gouma DJ. The effect of octreotide on gastric emptying at a dosage used to prevent complications after pancreatic surgery: a randomised, placebo controlled study in volunteers. Gut 1997;41(6):758-62.
54. Van Hee R, De Laet I, Salgado R, Ysebaert D. The influence of somatostatin on postoperative outcome after elective pancreatic surgery. Acta Chirurgica Belgica 1998;98(2):62-5.
55. Tian BL, Su AP, Wang WG, Zhang Y. Does preoperative somatostatin administration decrease the rate of postoperative pancreatic fistula following pancreaticoduodenectomy? A randomized placebo-controlled trial. Journal of Gastroenterology and Hepatology 2012;27 Suppl 5:359.
56. Wang W, Tian B, Babu SR, Zhang Y, Yang M. Randomized, placebo-controlled study of the efficacy of preoperative somatostatin administration in the prevention of postoperative complications following pancreaticoduodenectomy. Hepatogastroenterology 2012;60(123):e1. [DOI: 10.5754/hge12669].
57. Woltering EA. The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial - invited commentary. Journal of the American College of Surgeons 2003;196(4):564-5.
58. Yeo CJ. Does prophylactic octreotide benefit patients undergoing elective pancreatic resection?. Journal of Gastrointestinal Surgery 1999;3(3):223-4.
59. Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP. Current standards of surgery for pancreatic cancer. British Journal of Surgery 2004;91(11):1410-27.
60. Alghamdi AA, Jawas AM, Hart RS. Use of octreotide for the prevention of pancreatic fistula after elective pancreatic surgery: a systematic review and meta-analysis. Canadian Journal of Surgery 2007;50(6):459-66.
61. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al.Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005;138(1):8-13.
62. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al.The Clavien-Dindo classification of surgical complications: five-year experience. Annals of Surgery 2009;250(2):187-96.
63. Connor S, Alexakis N, Garden OJ, Leandros E, Bramis J, Wigmore SJ. Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery. British Journal of Surgery 2005;92(9):1059-67.
64. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
65. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
66. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Annals of Surgery 2004;240(2):205-13.
67. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
68. Forman D, Delaney B, Kuipers E, Malthaner R, Moayyedi P, Gardener E, et al.Cochrane Upper Gastrointestinal and Pancreatic Diseases Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2009, Issue 2. Art. No.: UPPERGI.
69. Gouma DJ, van Geenen RC, van Gulik TM, de Haan RJ, de Wit LT, Busch OR, et al.Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Annals of Surgery 2000;232(6):786-95. [PUBMED: 11088073].
70. Gurusamy KS, Gluud C, Nikolova D, Davidson BR. Assessment of risk of bias in randomized clinical trials in surgery. British Journal of Surgery 2009;96(4):342-9.
71. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
72. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, 2008.
73. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collsboration, 2011. Available from www.cochrane-handbook.org.
74. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
75. Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C, Koop I. Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 1987;36(2):108-24.
76. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20(4):641-54.
77. Mayo SC, Austin DF, Sheppard BC, Mori M, Shipley DK, Billingsley KG. Evolving preoperative evaluation of patients with pancreatic cancer: does laparoscopy have a role in the current era?. Journal of the American College of Surgeons 2009;208(1):87-95.
78. McKay A, Mackenzie S, Sutherland FR, Bathe OF, Doig C, Dort J, et al.Meta-analysis of pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy. British Journal of Surgery 2006;93(8):929-36.
79. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
80. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology 1992;21(5):837-41.
81. Ohwada S, Ogawa T, Tanahashi Y, Nakamura S, Takeyoshi I, Ohya T, et al.Fibrin glue sandwich prevents pancreatic fistula following distal pancreatectomy. World Journal of Surgery 1998;22(5):494-8.
82. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
83. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
84. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
85. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al.Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indicators. Journal of Gastrointestinal Surgery 2000;4(6):567-79.
86. StatsDirect Ltd. StatsDirect statistical software. Version 2.7.2. StatsDirect Ltd, 06/09/2008.
87. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine 2004;23(9):1351-75.
88. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336:601-5.
89. Gurusamy KS, Koti R, Fusai G, Davidson BR. Somatostatin analogues for pancreatic surgery. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD008370].
90. Koti RS, Gurusamy KS, Fusai G, Davidson BR. Meta-analysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: A Cochrane review. HPB 2010;12(3):155-65. [DOI: 10.1111/j.1477-2574.2010.00157.x].
91. Morris E, Wente MN, Seiler CM, Finch-Jones M, Büchler MW, Alderson D. Somatostatin and its analogues in the prevention of complications following pancreatic surgery. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD004521].